Evaluation of anti-Plasmodium falciparum antibodies in Senegalese adults using different types of crude extracts from various strains of parasite

Perraut, Ronald; Guillotte, Micheline; Drame, Idrissa; Diouf, Babacar; Molez, Jean-François; Tall, Adama; Trape, Jean‐François; Mercereau‐Puijalon, Odile; Spiegel, André; Garraud, Olivier

doi:10.1016/s1286-4579(01)01506-4

Cited by 34 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Microtiter plates were coated with 100 µl per well of MSP1p19 at a concentration of 0.5 µg/ml. Plasma samples were diluted 1:100 in PBS with 1% BSA /0.05% Tween 20, and ELISAs were performed as described previously [9,19,24]. 7 The results are expressed as OD ratios, i.e., OD sample /OD negative control .…”

Section: Antigens and Elisa Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Differential antibody responses to Plasmodium falciparum glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria

Perraut

Diatta

Marrama

et al. 2005

Microbes and Infection

Self Cite

View full text Add to dashboard Cite

Section: Antigens and Elisa Proceduresmentioning

confidence: 99%

“…The negative control was pooled plasma from Europeans not exposed to malaria. Positive responders were individuals with OD ratios > 2 (approximate mean OD + 2 SD of naive controls) [19,24]. For positive controls, ODs were ~0.45 (OD ratio of ~6) and ~1.6 (OD ratio of ~11) for GPI and MSP1p19, respectively.…”

Section: Antigens and Elisa Proceduresmentioning

confidence: 99%

Differential antibody responses to Plasmodium falciparum glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria

Perraut

Diatta

Marrama

et al. 2005

Microbes and Infection

Self Cite

View full text Add to dashboard Cite

“…We used standard SDS-PAGE on 12.5% gels under reducing conditions and immunoblotting to analyze the recombinant protein and parasite crude extracts as described elsewhere. 26 Separated proteins were stained with Coomasie brilliant blue silver stains (Sigma, St. Louis, MO). After blotting onto polyvinylidene difluoride membranes, antigen preparations were incubated for one hour with a 1:1,000 dilution of mice or monkey sera or with human immune plasma diluted in Tween 20-PBS (TPBS).…”

mentioning

confidence: 99%

Antigenicity, Immunogenicity, and Protective Efficacy of Plasmodium Vivax Msp1 Pv200l: A Potential Malaria Vaccine Subunit

Valderrama-Aguirre

Quintero

Gomez

et al. 2005

The American Journal of Tropical Medicine and Hygiene

117

View full text Add to dashboard Cite

Abstract. The merozoite surface protein 1 (MSP-1) is expressed in all Plasmodium species and is considered a major malaria vaccine candidate. We found that MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. The fragment, termed Pv200L, was expressed as a recombinant protein in Escherichia coli (rPv200L) and used to asses its immunologic relevance as a vaccine target. A cross-sectional, seroepidemiologic study conducted in Buenaventura, Colombia showed that 52.2% (95% confidence interval [CI] ‫ס‬ 39.8-64.3) of individuals previously exposed to P. vivax and 72.8% (95% CI ‫ס‬ 61.8-82.1) of P. vivax-infected patients had IgG antibodies to rPv200L. Immunization of BALB/c mice and Aotus monkeys induced IgG antibodies (titer > 10 6 ) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages. Our results suggest that Pv200L is a new malaria vaccine subunit and deserves further testing.

show abstract

“…share some common antigens [25,26] , but such antigenic similarities between plasmodia and Leishmania are not reported, although the two genera are phylogenetically closer. Nonspecifi c elevation of immunoglobulins in both malaria [27][28][29] and VL is reported [30,31] , which could be an explanation for the false-positive results among malaria patients.…”

Section: Discussionmentioning

confidence: 99%

Cross-Reaction of Sera from Patients with Various Infectious Diseases with <i>Leishmania infantum</i>

Kohanteb¹,

Ardehali²

2005

Med Princ Pract

View full text Add to dashboard Cite

Objective: To compare and evaluate the application of indirect fluorescent antibody (IFA) and counterimmunoelectrophoresis (CIEP) for laboratory identification of visceral leishmaniasis. Materials and Methods: Serum samples from patients with malaria (Plasmodium vivax, n = 86; Plasmodium falciparum, n = 38), brucellosis (n = 26), tuberculosis (n = 31) and typhoid fever (n = 35) were examined for the presence of antibody to Leishmaniainfantum antigen using IFA and CIEP tests. Results: Using IFA, false-positive results were malaria (P. vivax 19.8%, P. falciparum 13.2%), tuberculosis (6.4%), brucellosis (3.8%), and typhoid fever (2.8%). Using CIEP, a lower percentage of false-positives was observed only among malaria patients (P. vivax 2.3%, P. falciparum 2.6%). Serum samples from patients with other infectious diseases were negative in the CIEP test. Conclusion: Based on the results of this study, the CIEP technique is recommended for immunodiagnosis of visceral leishmaniasis, especially in regions where malaria, brucellosis and tuberculosis are prevalent.

show abstract

Evaluation of anti-Plasmodium falciparum antibodies in Senegalese adults using different types of crude extracts from various strains of parasite

Cited by 34 publications

References 20 publications

Differential antibody responses to Plasmodium falciparum glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria

Differential antibody responses to Plasmodium falciparum glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria

Antigenicity, Immunogenicity, and Protective Efficacy of Plasmodium Vivax Msp1 Pv200l: A Potential Malaria Vaccine Subunit

Cross-Reaction of Sera from Patients with Various Infectious Diseases with <i>Leishmania infantum</i>

Contact Info

Product

Resources

About